Clinical trials: Liver Transplant Recipients
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients
The purpose of this study is is to use non-invasive diagnostic tests, Fibroscan and a simple blood test, to diagnose NASH in patients who undergo liver transplantation.
- Trial name
- NCT03128918
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Liver Diseases
Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)
Researchers are interested in determining whether it is safe to reduce anti-rejection medication by approximately 50% after liver transplantation and whether special blood tests called biomarkers can identify early signs that the…
- Trial name
- BRITRE (NCT07862439)
- Testing
- miRNA Biomarker-Guided Immunosuppression Minimization, Conventional Biochemical Monitoring-Guided Immunosuppression Minimization
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Pennsylvania
Liver Disease (Alcoholic or Not), Liver Transplantation
Impact of Delta Model of End Stage Liver Disease (MELD) in High MELD Liver Transplant Recipients
Liver transplantation (LT) represents an important curative option for end stage liver disease such as decompensated cirrhosis, which remains a major challenge for today's health care system.
- Trial name
- HDMELD in LT (NCT07570901)
- Where
- 2 sites in Canada, Germany
- Volunteers
- 446 people
- Sponsor
- University of Jena
Liver Transplantation, Hepatitis C
Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.
Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.
- Trial name
- EGRADICATE (NCT02890719)
- Testing
- Grazoprevir 100 mg/day, Elbasvir 50 mg/d, Elbasvir 50 mg/day
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Acute Liver Failure, Acute-On-Chronic Liver Failure
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Efficient immunosuppressive therapy and improved surgical techniques have developed liver transplantation as a well-established and life-saving treatment. The 1-year survival rate of approximately 85-90%.
- Conditions
- Acute Liver Failure, Acute-On-Chronic Liver Failure, Liver Cirrhosis
- Trial name
- NCT04621812
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis C
LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
The predominant remaining questions for post-transplant treatment of Hepatitis C virus (HCV) in the DAA (direct acting anti-virals) era are whether a ribavirin-free regimen is possible and whether pre-emptive treatment is now a…
- Trial name
- NCT02631772
- Testing
- Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Medical University of South Carolina
End-stage Liver Disease
Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients
'ThRIL' aims to explore the feasibility, safety and efficacy of TR002, a regulatory cell therapy, as adjunct immunosuppressive treatment in the context of liver transplantation
- Trial name
- ThRIL (NCT02166177)
- Testing
- Autologous regulatory T cell product
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Liver Transplantation
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.
- Trial name
- HEPHAISTOS (NCT01551212)
- Testing
- Everolimus, Tacrolimus, Corticosteroids
- Where
- 15 sites in Germany
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplant Disorder, Self Efficacy
Effectiveness of Intelligent Case Manage Platform in Liver Transplant Recipients
This study is a prospective, quasi-experimental design, with an experimental group and a control group, will be created. The aims of this study are as follows: 1.
- Conditions
- Liver Transplant Disorder, Self Efficacy, Quality of Life
- Trial name
- ICMP (NCT05953948)
- Testing
- Intelligent Case Manage Platform (ICMP) and self-management program
- Where
- Taiwan
- Volunteers
- 333 people
- Sponsor
- Chang Gung University
Liver Transplant; Complications, Liver Failure, Acute
Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy.
- Trial name
- NCT06263114
- Testing
- TruGraf® Liver gene expression panel (GEP)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Children's Mercy Hospital Kansas City
Medication Adherence, Liver Transplant Disorder
Text Messages for Liver Transplant Recipients
Although medical advancements have enabled children experiencing liver transplants to live longer, medical management post-transplant is ongoing and complex.
- Trial name
- NCT04995770
- Testing
- Praise Text Messages
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Children's Hospital Los Angeles
Liver Transplant
Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully…
- Trial name
- NCT06043531
- Testing
- Experimental: EVOO
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Virginia Commonwealth University
Cytomegalovirus Infection
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
This is a trial of preemptive therapy vs. prophylaxis for prevention of Cytomegalovirus (CMV) disease in R-D+ liver transplant patients.
- Trial name
- NCT01552369
- Testing
- Valganciclovir
- Where
- 6 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant, Liver Transplantation
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
The primary aim of this study is to determine whether a peripheral blood or graft lymphocyte phenotype of immune senescence or exhaustion is different between operationally tolerant and non-tolerant liver allograft recipients.
- Trial name
- OPTIMAL (NCT02533180)
- Testing
- Immunosuppression withdrawal
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant Disorder, Vitamin D Deficiency
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Interest in vitamin D has seen an unprecedented revival sparked by the finding that vitamin D has pleiotropic effects with an intriguing link to the critically ill patients.
- Trial name
- D-LIVER-X (NCT03234218)
- Where
- Italy
- Volunteers
- 68 people
- Sponsor
- The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Cytomegalovirus Infection
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
The purpose of this study is to assess the effect of pre-transplant mRNA-1647 on post-transplant cytomegalovirus (CMV) virologic outcomes, anti-CMV antiviral use, and clinical outcomes in CMV-seropositive and CMV-seronegative…
- Trial name
- NCT06133010
- Testing
- mRNA-1647
- Sponsor
- ModernaTX, Inc.
Physical Activity After Organ Transplantation
High-intensity Training Safely Improves Exercise Capacity in Heart, Lung, Kidney, and Liver Transplant Recipients: a Comparative Study
The investigators will investigate whether high-intensity exercise training can safely improve physical performance in long-term stable heart, kidney, lung, and liver transplant recipients.
- Trial name
- NCT03329586
- Testing
- High-intensity training
- Where
- Belgium
- Volunteers
- 42 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Complication, Post Operative Complication
Lung Ultrasound Score as Post Operative Predictive Value of Pulmonary Complications in Living Liver Transplant Recipient
The aim of this study is to determine if lung ultrasound score has a strong predictive value for post operative pulmonary complications in living liver transplant recipient
- Trial name
- NCT06498895
- Testing
- lung ultrasound
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Liver Transplant Recipients
The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant
This research study is being done to study the effects, both good and bad, of calcineurin inhibitors and the drug Cozaar (losartan), on kidney function and kidney scarring following a liver transplant.
- Trial name
- NCT00275639
- Testing
- Cozaar
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Mayo Clinic
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.